Clinical Trial Update: A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update outlines a combined Phase 2/3 study of PPI-668 (NS5A inhibitor) with Sofosbuvir, with or without Ribavirin, for chronic hepatitis C g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PPI-668
• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Pharco Pharmaceuticals | Conditions: Chronic Hepatitis C | Phase 2, Phase 3 | Status: UNKNOWN